BioMed Realty Trust CEO Alan D. Gold Sells 25,000 Shares (BMR)
BioMed Realty Trust (NYSE:BMR) CEO Alan D. Gold unloaded 25,000 shares of the stock on the open market in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $21.18, for a total transaction of $529,500.00. Following the completion of the transaction, the chief executive officer now directly owns 459,177 shares in the company, valued at approximately $9,725,369. The sale was disclosed in a legal filing with the SEC, which is available at this link.
BMR has been the subject of a number of recent research reports. Analysts at Robert W. Baird raised their price target on shares of BioMed Realty Trust from $22.00 to $23.00 in a research note on Tuesday. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of BioMed Realty Trust in a research note on Thursday, April 17th. They now have a $23.00 price target on the stock. Finally, analysts at Cowen and Company raised their price target on shares of BioMed Realty Trust from $20.00 to $22.00 in a research note on Tuesday, March 11th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $22.71.
Shares of BioMed Realty Trust (NYSE:BMR) traded down 0.42% during mid-day trading on Thursday, hitting $21.12. 1,184,423 shares of the company’s stock traded hands. BioMed Realty Trust has a one year low of $17.90 and a one year high of $23.13. The stock’s 50-day moving average is $20.5 and its 200-day moving average is $19.64. The company has a market cap of $4.032 billion and a price-to-earnings ratio of 86.22.
BioMed Realty Trust (NYSE:BMR) last announced its earnings results on Wednesday, April 30th. The company reported $0.38 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.35 by $0.03. On average, analysts predict that BioMed Realty Trust will post $1.47 earnings per share for the current fiscal year.
BioMed Realty Trust, Inc operates as a real estate investment trust (NYSE:BMR), and the general partner of BioMed Realty, L.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.